Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.

“The LymPro Test is potentially the first available blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014.”

Amarantus and BD Biosciences will be focused on verifying the analytical performance characteristics of LymPro necessary to achieve reproducibility of the assay. Over time, Amarantus expects to execute multiple clinical studies and begin worldwide sales of LymPro as the first diagnostic blood test for Alzheimer’s disease.

About Amarantus

 Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson’s disease and Alzheimer’s disease. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.Tweet

The importance of understanding and evaluating the GI system is evident with recent scientific advances in diseases such as colon cancer, inflammatory bowel disease, and chronic diarrhea, and in disorders such as autism, allergy, and obesity. It is believed that new and improved laboratory tools that enable a better understanding of gut function could have a significant impact on diagnosing, treating, curing, and preventing such diseases and disorders. Furthermore, the ability to better evaluate GI function, especially through simple and non-invasive means, could have a significant impact on decreasing the cost and increasing the quality of healthcare worldwide.

In their publication, Dr. Kristal and colleagues reported that the combination of PBI’s patented pressure cycling technology (“PCT”) platform and certain chemicals improved the extraction of lipids from fecal material.  They concluded that their new method “opens the door to the use of fecal lipid profiling for both scientific and clinical applications” and that it “provides a reproducible, generally applicable, broad-based, and non-invasive technique for establishing gut function in patients regardless of age or disease.”

Further, the authors stated that the study “represents a new paradigm for determining the impact of initial intestinal colonization and for assessing nutritional, infectious, and inflammatory status” in premature infants.  They proposed that the method might be useful in other strategies for monitoring the GI system and might help improve care for vulnerable patients with conditions such as inflammatory bowel disease, ulcerative colitis, and gastrointestinal cancers.

Dr. Nate Lawrence, VP of Marketing and Sales for PBI, said, “We believe this novel method can help determine and assess intestinal function, response to nutrition, inflammation, and even the occurrence and/or progression of disease. We further believe that it could have both diagnostic and prognostic implications on vulnerable and difficult-to-study populations, such as premature infants and the elderly.  We are thrilled that our PCT platform is an important part of this exciting, potentially paradigm-changing method, one which we believe could play a significant role in future research and clinical applications.”

The authors stated that to their knowledge this publication was the first report of full intact lipid extraction from fecal material followed by LC-MS analysis.  The analysis of intact lipids is important as it results in better biological information compared to non-intact lipids. LC-MS is a popular method widely-used by research scientists worldwide in the study of proteins and lipids.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on our proprietary technology – pressure cycling technology. PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterrorism applications.

Forward-Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the breakthrough method for the extraction and analysis of lipids from fecal material; the importance of understanding and evaluating the GI system; that new and improved laboratory tools could have a significant impact on diagnosing, treating, curing, and preventing diseases and disorders; that the ability to better evaluate GI function, especially through simple and non-invasive means, could have a significant impact on decreasing the cost and increasing the quality of healthcare worldwide; that the new method opens the door to the use of fecal lipid profiling for both scientific and clinical applications and provides a reproducible, generally applicable, broad-based, and non-invasive technique for establishing gut function in patients regardless of age or disease; that the study represents a new paradigm for determining the impact of initial intestinal colonization and for assessing nutritional, infectious, and inflammatory status in premature infants; that the method might be useful in other strategies for monitoring the GI system and might help improve care for vulnerable patients with conditions such as inflammatory bowel disease, ulcerative colitis, and gastrointestinal cancers; that the novel method can help determine and assess intestinal function, response to nutrition, inflammation, and even the occurrence and/or progression of disease; that the new method could have both diagnostic and prognostic implications on populations such as premature infants and the elderly; that the method could play a significant role in future research and clinical applications; that this publication was the first report of full intact lipid extraction from fecal material followed by LC-MS analysis; that the analysis of intact lipids is better than the analysis of non –intact lipids; and the size of the life sciences sample preparation market.  These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company’s strategies that may adversely affect the Company’s continued commercialization of its PCT-based product line; changes in customer’s needs and technological innovations; the Company’s and its strategic partners/distributors sales forces may not be successful in selling the Company’s PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported or see the advantages of using the Company’s PCT platform in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond June 2013. Further, given the uncertainty in the capital markets and the current status of the Company’s product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond June 2013 on acceptable terms, if at all.  These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on: Facebook, LinkedIn, and Twitter

Investor Contacts:
Richard T. Schumacher, President & CEO, PBI (508) 230-1828 (T)Tweet

Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced a development timeline for its LymPro Blood Test for Alzheimer’s disease (“LymPro”). LymPro is designed to diagnose Alzheimer’s disease by identifying immune-based biomarkers in the blood of Alzheimer’s patients, allowing physicians to definitively differentiate Alzheimer’s disease from other forms of dementia, a key unmet medical need in the management of Alzheimer’s patients. Human clinical studies for LymPro with over 160 patients have been completed to date, showing high sensitivity and specificity for Alzheimer’s disease diagnosis.

“The LymPro assay represents a blood-based peripheral means to assess the integrity of the regulatory function of the cellular machinery within the Central Nervous System,” said Amarantus corporate advisor Adam J. Simon, Ph.D. “Although we all experience various triggers and assaults on our brain as we age, why do some people succumb to Alzheimer’s while others show cognitive resilience? The LymPro test can potentially tell us who is susceptible to abnormal cell-cycle re-entry and who has sufficiently strong regulatory function in their neurons to arrest cell-cycle re-entry due to triggers such as age, diet, viral infection, stress, or brain injury that could eventually lead to Alzheimer’s disease.”

After establishing the analytical performance of the assay in an outsourced GLP laboratory, Amarantus plans to conduct a small clinical performance study at an independent laboratory in the second quarter of 2013 to verify the previously published findings. During the third quarter of 2013, the Company expects to initiate a pivotal diagnostic accuracy study (Phase 2) at the same independent laboratory to generate sufficient data to validate the clinical performance (sensitivity / specificity) that would support a CLIA launch, with data available in the first half of 2014. As part of that pivotal study, LymPro will be evaluated as an “aid to the diagnosis of Alzheimer’s disease.” The Company intends to initiate commercial worldwide sales following assessment of the validation study data. Thereafter, the Company intends to gain U.S. clearance or approval for the test through the Food and Drug Administration’s de-novo Pre-market notification 510(k) or Premarket Approval (PMA) process, which would represent a 3-month to 2-year process. Ultimately, the Company believes LymPro could be approved by the FDA as a companion diagnostic product in combination with one or more therapeutic products.

“We are excited with the progress and upcoming activities related to our LymPro Alzheimer’s test, which addresses a market opportunity in excess of $500 million annually,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus. “The FDA has stated the importance of identifying Alzheimer’s at the earliest stage, as that is where new treatments appear to have the greatest benefit to patients. We believe LymPro fits well within this overall strategy and will likely have the dual benefit of improving overall diagnosis paradigms and accuracy, while also potentially reducing overall healthcare costs if combined with an appropriate therapeutic product as a companion diagnostic.”

The field of diagnostics for Alzheimer’s disease has been significantly bolstered in recent months with FDA guidance for drug developers to target experimental therapies of Alzheimer’s disease towards earlier-stage patients, as well as guidance reducing the burden of proof for drug developers to gain an approval. In 2010 Eli Lilly & Co. acquired Alzheimer’s diagnostic developer Avid Radiopharmaceuticals for $800 million, including $300 million up-front, following Avid’s application for marketing approval to the FDA for florbetapir, a chemical agent used in the diagnosis of Alzheimer’s disease during a PET imaging process. Amarantus believes that LymPro may have certain advantages over florbetapir, including the likely cost-effectiveness of LymPro as a simple blood test in comparison to more expensive neuro imaging techniques.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates for Alzheimer’s and Parkinson’s disease, and the potential market size for the LymPro test for Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Tweet

By Grant Zeng, CFA
Another Strong Quarter of Product Sales is Expected 

After booking record sales of PCT products in third quarter of 2012, we are expecting another strong quarter of product sales for fourth quarter of 2012.

We estimate product sales of $0.32 million for the fourth quarter of 2012, a 79% increase compared to $0.18 million product sales of 4Q11. These product sales include PCT equipment and consumables.

Grant revenue is expected to be $0.10 million for 4Q12, compared to $0.16 million for 4Q11.

Total revenue based on our estimate will be $0.42 million for the fourth quarter of 2012, compared to $0.34 million for the fourth quarter of 2011, an increase of 25%.

Gross margin for product sales is estimated to be 65.6% for the 4Q12, compared to 48.5% for the 4Q11, a 35% improvement.

Operating loss is expected to be $0.7 million for the 4Q12, compared to operating loss of $0.9 million for 4Q11, a 22% improvement.

We estimate that net loss will be $0.9 million or $0.08 per share, compared to net loss of $2.0 million or $0.30 per share.

Based on the improvements of financial results for the last three quarters of 2012, and the aggressive commercialization strategy the Company has implemented in 2012, we expect revenue will enter into high growth in 2013 and beyond. From 2012 to 2015, net product sales will grow at amazing 118% compound annual growth rate (CAGR). PBIO will become profitable in fiscal 2015 with EPS of $0.06 based on total revenue of $11 million.

We think the share price of PBIO is undervalued. At this time, the downside risk is low while upside potential is high for the Company.

Leadership Strengthened by Appointing New Chief Financial Officer

On December 5, 2012, Pressure BioSciences, Inc. (OTC Markets:PBIO) announced that Mr. Conrad F. Mir has joined the Company as its chief financial officer, effective immediately.

Mr. Mir has over twenty years experience in investment banking, financial structuring, and corporate reengineering. He has served in various executive management roles and on the Board of Directors of several companies in the biotechnology industry. Most recently, Mr. Mir was chairman and CEO of Genetic Immunity, Inc. (:GI), a plasmid, DNA company in the HIV space. Prior to GI, Mr. Mir served as executive director of Advaxis, Inc., a vaccine company. During his tenure at GI and Advaxis, Mr. Mir was responsible for raising nearly $40 million in growth capital and broadening corporate reach to new investors and current shareholders.

Prior to GI and Advaxis, Mr. Mir worked for several investment banks including Sanford C. Bernstein, First Liberty Investment Group, and Nomura Securities International. He holds a BA/BS in Economics and English with special concentrations in Mathematics and Physics from New York University.

PBIO recently announced record PCT product sales for the third quarter of 2012, and we expect another strong quarter of product sales for the 4Q12. The Company has implemented aggressive commercialization strategy in 2012 to accelerate the revenue growth of its patented PCT products and services which included, among other things, an increase in international sales and distribution coverage from three to over twenty countries. But PBIO needs to properly finance this initiative. This is currently the biggest concern.

We believe the strong investment banking background of Mr. Mir will help PBIO raise new capital to fund its operations. It is also one of Conrad’s best strengths. He has proven over the past few years that he has the ability to raise significant funds for small, developing companies in a smart and timely way.

Please visit SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.

Read the Full Research Report on PBIOTweet

The Agreement includes purchase of Balqon’s proven electric drive system, featuring its proprietary ZEVQON™ Flux Vector AC controller, and HIQAP™ high-energy lithium batteries. Both companies will provide engineering resources for integration, testing and certification of the product for on-road use in China and North America.

“With the recent introduction of electric taxis in Sichuan Province, we have been leading the effort in design and development of electric passenger vehicles in West China,” said Mr. Cao Guodong, President of Sichuan Automobile Industry CO. Ltd. “This agreement with Balqon Corporation allows us to leverage their experience and technical expertise in the heavy duty truck and electric bus market,” he added.

“China’s recent regulatory initiatives and incentives to reduce diesel powered vehicle emissions helps commercial viability of new technology electric vehicles,” said Balwinder Samra, CEO and President of Balqon Corporation. “The increased rate of urbanization in China has led to renewed emphasis on reducing air pollution resulting from diesel powered buses in the urban centers throughout China,” he added.

Sichuan Automobile Industry Co. Ltd is a subsidiary of Fulin Group which owns and operates over 5,000 diesel inner city buses in West China and is recently recipient of several grants from the Chinese government to produce low emission vehicles.

About Sichuan Automobile Industry Co., Ltd

Sichuan Automobile Industry Co., Ltd (SAIG) was founded in the 1980s and is a fully owned subsidiary of Fulin Group. Fulin Group has five subsidiaries that include bus manufacturing, passenger car manufacturing, engine assembly plant, distribution and a Service Company that operates inner city buses. SAIG is a leading manufacturer and operator of inner city transit buses, taxis, SUVs and passenger cars. SAIG is known for many nationally renowned car brands such as “Jinding” (bus), “Yema” (light-off-road vehicle) and “Bailu” (Mini-vans). SAIG is the only carmaker in Sichuan province that has both commercial vehicle (bus) and passenger vehicle (light bus) production facilities and is listed in the 12th Five-Year Government Plan of Sichuan Province. SAIG has two production facilities located in Chengdu and Mianyang city. For more information, please visit http://www.yemaauto.cn.

About Balqon Corporation

Headquartered in Harbor City, California, Balqon Corporation is a leading developer of zero-emissions electric drive systems, lithium battery storage systems and medium to heavy-duty electric vehicles. Balqon’s proprietary electric drive system encompasses complete power management, propulsion, flux vector motor controllers and energy systems. Balqon electric vehicles and drive systems are marketed globally to companies, governments and municipalities looking for viable and effective ways to reduce their vehicle maintenance and operating costs and lower carbon emissions. Balqon is recognized as a pioneer in commercial electric vehicle technology and development of energy efficient transportation solutions. For more information, please visit www.balqon.com.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of ability to attract sufficient capital and labor to manufacture its products; the ability of Balqon Corporation to attract and retain talented individuals and other factors affecting the Company and its operations, markets, product, the impact on the China and North American economies resulting from economic slowdown, change in governmental regulation and policies and risks previously and from time to time disclosed in Balqon Corporation’s filings with the Securities and Exchange Commission, including, specifically, those factors set forth in the “Risk Factors” section of Balqon Corporation’s most recent Quarterly Report on Form 10Q filed with the Securities and Exchange Commission.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130313005474/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50589578&lang=en

Tweet

Mr. Jeffrey N. Peterson, Chairman of the PBI Board of Directors, said: “Mickey’s technical experience, gained from bench scientist to widely-recognized R&D leader spanning multiple successful cutting-edge technologies, will contribute strongly to the selection and development of key markets for our patented pressure cycling technology (“PCT”) platform.  His entrepreneurial success in founding and leading nationally-acclaimed companies in biomarker discovery, personalized medicine, and healthcare strategic consulting will be immensely useful as we continue our aggressive PCT commercialization strategy. We are honored and privileged to welcome Mickey to the PBI Board.”

Dr. Mickey Urdea commented: “Since being introduced to PCT just three months ago, I have become fascinated with the current applications and extensive future potential uses of this cutting-edge technology platform. Over the years, I have helped develop and then support the marketing of many new technologies, several of which made significant impacts in the research and diagnostic marketplaces. To that end, I believe PCT has the potential to gain widespread adoption and become a vital sample preparation tool to research and clinical laboratories worldwide. I am very pleased to join the PBI Board, and look forward to helping Ric, his impressive team, and my new colleagues on the Board of Directors make as many scientists and investors as possible aware of the power of PCT.”

Mr. Richard T. Schumacher, President and CEO of PBI, said: “On behalf of all PBI stakeholders, I extend my deep appreciation and best wishes to Wayne Fritzsche for his nearly eight years of tireless and dedicated service to our company, most of which were spent as chairman. His leadership has helped bring PBI to the point where, we believe, we are well positioned to successfully commercialize our powerful PCT Platform, as well as our other pressure-based products.  It is fitting that as Wayne moves off the Board, he moves into a full-time, management position in PBI where he can significantly affect our future, commercial success.”

About Dr. Urdea

Dr. Urdea has devoted his 30-year career to human diagnostics in a variety of capacities. He has been involved in the discovery of new biomarkers, the development of new technologies for biomarker discovery, validation and commercialization, diagnostic test development, manufacturing and marketing, and the management of companies involved in these activities. Dr. Urdea founded and is a Managing Partner for Halteres Associates, a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company involved in preventative personalized medicine. Tethys’ first product was the protein-based PreDx Diabetes Risk Score Test, which was introduced in 2008. Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health, an organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. He serves as an expert consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology, diagnostics, venture capital and philanthropic organizations.

Prior to his current business activities, Dr. Urdea founded the Nucleic Acid Diagnostics group at Chiron Corporation, and with colleagues, invented branched DNA molecules for amplification of signal in nucleic acid complexes. Application of this technology resulted in the first commercial products for quantification of human hepatitis B, hepatitis C, and human immunodeficiency viruses (HBV, HCV, and HIV, respectively). He then became business head of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics.  He was also a member of the Bill and Melinda Gates Foundation Diagnostic Forum.

Dr. Urdea is an author on nearly 200 peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued and pending patents. He received his BS in Biology and Chemistry from Northern Arizona University in Flagstaff and his Ph.D in Biochemistry from Washington State University in Pullman.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology. PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the value that Dr. Mickey Urdea is expected to contribute to the PBI Board of Directors and to the Company; that PCT has the potential to gain widespread adoption and become a vital sample preparation tool to research and clinical laboratories worldwide; the value that Mr. Wayne Fritzsche is expected to contribute to the commercial success of the PCT Platform and the Company’s other pressure-based products in his new management position with the Company; the size of the sample preparation market; and the applications for, and the competitive advantages of, the PCT Platform. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company’s strategies that may adversely affect the Company’s continued and expanded commercialization of its PCT-based product line; changes in customer’s needs and technological innovations; and the Company’s sales force and distribution network may not be successful in selling the Company’s PCT-based product line because scientists may not perceive the advantages of PCT over other sample preparation methods.  Further, given the uncertainty in the capital markets and the current status of the Company’s product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond March 2013 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com

Tweet

Balqon Corporation (OTCBB: BLQN), a developer of electric vehicles, drive systems and lithium battery storage devices, announced delivery and installation of HIQAP™ high energy storage 1000 ahr, 48 volt battery system into Island Pilot Yacht, America’s First Hybrid Yacht, powered by DSE Hybrid solar electric drive. The Battery System delivered included lithium batteries, Balqon proprietary Battery Management System, Charger and CAN Bus control systems to safely manage charge and discharge of batteries during daily operation.

“We have been seeking high energy density battery solution that was economical and provided longer run time with higher transfer efficiency,” said Rueben Trane, Executive Director of Island Pilot. “Powering our Hybrid Yacht with Balqon HIQAP™ battery system that includes battery management and charger addressed our need for an economical, plug-n-play lithium battery solution.”

Balqon HIQAP™ battery system is designed to be a direct replacement of lead acid batteries in the transportation and energy storage applications. HIQAP™ 1000 ahr lithium battery system includes integrated Balqon proprietary battery management and control system with CAN Bus controlled Charger. System also includes relay control for Solar Charge Controller and power Inverter controls to safely charge and discharge lithium battery pack.

“Our proprietary 1000 ahr capacity single cell battery design enables our customers to upgrade from lead acid batteries to higher transfer efficiency lithium solutions with minimum effort,” said Balwinder Samra, CEO of Balqon Corporation. “By using our fully integrated battery system, our customers save integration time and development costs”, he added.

DSE Hybrid yacht equipped with lithium battery system will be on display at a Boat show called Trawlerfest held at Bahia Mar Marina in Fort Lauderdale, Florida from Jan 31^st to February 2^nd, www.trawlerfest.com.

About DSE Hybrid

DSE Hybrid is manufacturer and integrator of solar power electric drive systems in marine applications. Located in Key Largo, Florida, DSE Hybrid operates Island Pilot, 12 meter hybrid yacht for green cruising tours. DSE Hybrid (http://www.dsehybrid.com/) is America’s first solar powered 12m yacht that provides daily eco tours in south Florida.

About Balqon Corporation

Headquartered in Harbor City, California, Balqon Corporation is a leading developer of zero-emissions electric drive systems, lithium battery storage systems and medium to heavy-duty electric vehicles. Balqon’s proprietary electric drive system encompasses complete power management, propulsion, flux vector motor controllers and energy systems. Balqon electric vehicles and drive systems are marketed globally to companies, governments and municipalities looking for viable and effective ways to reduce their vehicle maintenance and operating costs and lower carbon emissions. Balqon is recognized as a pioneer in commercial electric vehicle technology and development of energy efficient transportation solutions. For more information, please visit http://balqon.com/store.php. Balqon Corporation’s common stock trades on the OTC Bulletin Board under the symbol “BLQN”. Follow us on Twitter @balqon or http://twitter.com/#!/balqon or visit our Facebook page at: http://www.facebook.com/balqoncorporation.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

With the exception of historical information, the matters discussed in this press release, including without limitation, whether the HIQAP™ will provide its users with longer run time, lower operating costs than the operating costs incurred by users of deep cycle lead acid batteries are forward looking statements that involve a number of risks and uncertainties. The actual future results of Balqon Corporation could differ from those statements. Factors that could cause or contribute to such differences include, but are not limited to, market acceptance of the Balqon’s technologies and solutions; unforeseen technical issues; Balqon Corporation’s ability to attract sufficient capital and labor to manufacture its products; the ability of Balqon Corporation to attract and retain talented individuals; adverse economic and market conditions; the projected future demand for Balqon Corporation’s products, including the changes in technology and governmental regulations and policies; and other events, factors and risks previously and from time to time disclosed in Balqon Corporation’s filings with the Securities and Exchange Commission, including, specifically, those factors set forth in the “Risk Factors” section of Balqon Corporation’s most recent Annual Report on Form 10-K and Quarterly Report for the nine month ended September 30, 2012 filed with the Securities and Exchange Commission.

Tweet

On January 7^th, Balqon Corporation (OTC.QB: BLQN), stalwart of the electric vehicle and lithium battery storage industries, renewed the faith of investors once again by receiving a handsome grant in the amount of $925,000 issued by the Los Angeles Department of Energy and administrated by the South Coast Air Quality Management District.  The grant is a commission to develop three Model MX-30 electric trucks for drayage applications around the Port of Los Angeles and Long Beach, and it comes on the heels of a string of other notable accomplishments made by the fledgling tech company throughout the past year.

Currently selling at .18 cents a share with a market cap of 7.38M and an average volume of 9,174, Balqon’s main interest of designing, developing, and distributing advanced cargo vehicles for industrial applications is compounded by its endeavors in building vehicles for public transportation and furnishing them with cutting edge battery production.  Having recently been spotlighted in a Forbes online journal article on electric buses, Balqon’s ambitious variety of endeavors have positioned them with the potential to become one of the worldwide leaders in clean energy, and their generous new grant allows them to combine and develop many of their most recent technological advances in a unique way. In addition, Balqon is the only heavy duty truck manufacturer that has developed their own proprietary inverter and charger technologies for use in trucks and buses.

The Model MX30 commissioned for development by the grant is a Class 8 electric tractor introduced by Balqon in May of 2012.  Used for short haul drayage and inner city applications, the MX30 is one of the most revolutionary electric vehicles on the market, reaching speeds of up to 70MPH and carrying loads of over 30 tons.  It can travel up to 150 miles on a single three-hour charge.

But in addition to the opportunity to develop more electric vehicles, Balqon, a company which has recently made major strides into the industry of lithium battery storage, has expressed particular interest in this project because, as noted by CEO Balwinder Samra, it also allows Balqon to utilize in-house, proprietary energy storage technologies for the trucks.

“This project will help us develop and demonstrate short charge times by using lithium battery energy storage systems we have developed for renewable and energy storage industries,” said Samra.

Among those storage systems is Balqon’s relatively new series of lithium batteries called HIQAP™, introduced to the market on July 30^th of last year.  Intended to replace current lead acid battery technologies, the HIQAP™ model uses a low internal resistance which has been tested to be 15% more efficient during energy transfer than the current comparable lead and acid batteries.  HIQAP™ is also being marketed as a green alternative to environmentally unfriendly lead batteries, and a modified version of the battery has even been put to use in electric powered airport baggage tractors.

Thanks to these advances in battery system productions, as well as a significant boost in their online presence, Balqon has reported that 10% of their 2012 second quarter revenue resulted from battery sales through their website, with numbers of online sales steadily increasing throughout the year.  Given the company’s prior experience and accomplishments in the field of electric vehicles, this shift of focus into lithium battery energy storage has made Balqon a force to be reckoned with in the arena of clean energy tech companies.

With a quickly expanding arsenal of vehicles and battery products gaining traction around the globe, and its roots firmly planted with electric vehicles that operate in the Port of Los Angeles, Balqon Corporation may just be the next big thing in clean energy production.  Investors interested in green energy and technology should put Balqon on the radar today.

Always read full disclaimer/disclosure pertaining to this article: http://tomorrowsbluechips.com/disclaimer/

 Tweet

Pressure BioSciences, Inc. (PBI) (OTCQB: PBIO), currently trading at $0.30 per share with a market cap of $3.51 million, began operations in mid-2007 out of Massachusetts. Since then, they have focused on the development, marketing and sales of proprietary lab instruments and related consumables based on their patented, powerful technology platform called Pressure Cycling Technology (PCT). With their Barocycler instruments, consumable products (processing reaction tubes and isolation kits that put molecules into workable states for a wide variety of lab applications), and their increasingly impressive sales record, PBIO broke through in 2012. Let us count the ways that this promising small cap ended the year in high style.

1)      Sales and Revenue – At first glance, it may seem like the sales of Pressure BioSciences’ implicitly technical product line would be fated to plateau after fulfilling the demand of a few niche industries in the sample preparation market. However, PCT can prepare valuable samples for a whole spectrum of purposes and industries including FBI forensics, counter-bioterrorism, soil biology, plant biology, histology, vaccine development and bio-therapeutics characterization amongst others. All in all, these fields add up to an estimated $6 billion life sciences sample preparation market, which may help explain PBIO’s climb over the last year. The sales of PCT products and services increased 37 percent for the third quarter. Sales of PCT-based consumables were up 33 percent, and total revenue saw a jump of 40 percent. In addition, operating loss, cash burn and loss per common share all went down. Joseph L. Damasio, Vice President of Finance and Administration, said, “We worked hard to increase revenue while reducing our operating loss, with evident success for both. On the financing side, we received approximately $600,000 in short-term loans from five investors during the third quarter, including two members of the Board of Directors. We are very pleased with our financial performance for both the third quarter and the year-to-date period ending September 30, 2012.”

2)      New Blood – Nothing keeps a company edgy and competitive like new blood and fresh ideas. As its momentum grew, PBIO recruited investment banking veteran Conrad Mir as their new Chief Financial Officer to raise funds in a quick and efficient way. Mr. Mir had this to say: “I look forward to being a part of the management team at Pressure BioSciences. It is my intent to help develop and implement a sustainable fiscal road map that can increase shareholder value by supporting continued growth, particularly in the marketing and sales area. I am grateful for the opportunity to help define the Company’s future.”

3)      Strategic Partnership – On November 26, PBIO and Constant Systems Ltd. announced that the two companies have entered into a two-way, strategic marketing, selling and distribution agreement until December 31, 2013 at the very least.  Under the terms of the Agreement, PBI has been awarded non-exclusive rights to market, sell, and distribute CS’s unique, high pressure cell disruption equipment and consumables in the United States, Canada, and Mexico while CS has been awarded the rights to market, sell, and distribute PCT based instruments and consumables in England, Scotland, Wales, Ireland, Spain, Portugal, Italy, Norway, Sweden, Finland, Denmark and Singapore.  This expands PBIO’s coverage to 12 new countries, and neither company has qualms about sharing booths at trade shows or combining ads, webcasts and email campaigns.

4)      Cole-Parmer Agreement – Most importantly, however, PBIO now has shared interests with Thermo Fisher (TMO) – a world leader in science service with revenues of approximately $12 billion. In early November, Thermo Fisher subsidiary, Cole-Parmer, announced an agreement to carry PBIO’s Shredder SG3 system for purchase on its Web site. For Cole-Parmer, the benefit is the instrument itself. The PBI Shredder SG3 System is ideal for the extraction of DNA, RNA, protein, mitochondria and small molecules while maximizing safety and sample integrity. The device offers a uniquely closed system for preparing samples compared to its competitors that are generally open systems. For PBIO, the benefits of this momentous agreement are more obvious: Cole-Parmer happens to be one of the world’s largest and most recognized distributors of lab equipment and supplies.  This means increased visibility for PBIO’s superior product line as well as boosted sales as Cole-Parmer’s catalogs land in the hands of laboratory scientists all over the globe.

Other successes in 2012 included: strategic partnerships with LEAP Technologies, Sage-N Research, and Valco Instruments; expanded license agreement and collaboration with cancer management company Target Discovery; collaboration with world-famous forensic scientist Dr. Henry Lee; and the presentation of important data generated using PBI’s instruments by scientists from a number of leading institutions, including UCLA, University of North Texas, the FDA, Janssen (a J&J company), Cernomics Solutions, and Florida International University.,

So, as PBIO takes the reins for 2013, investors should take notice. When it comes to PBIO’s potential, the sky is the limit. For more information, please visit www.pressurebiosciences.com

Always read our full disclaimer/disclosure pertaining to this article
http://tomorrowsbluechips.com/disclaimer/Tweet

For years, industry giants Talison Lithium (TSE: TLH), FMC Corporation (NYSE: FMC), Sociedad Quimica y Minera (NYSE: SQM) and Chemetall controlled approximately 95 percent of the lithium market, which limited supply and maximized exclusivity. However, the recent purchase of Talison Lithium (TSE: TLH), the largest of all, for $732 million by Rockwood Holdings (Chemetall) has shaken things up. The transaction took the Canadian-listed company private at almost $6.60 per share – a 50 percent premium to its pre-offer trading price.

This purchase highlights and magnifies the value of lithium in today’s global economy, while potentially enhancing prospects for other lithium companies – especially junior exploration companies like AmeriLithium Corp. (OTCQB: AMEL). Meanwhile, large mining companies looking for lithium exposure are more likely to acquire late-stage exploration companies than pay a premium for one of the three producing giants.”

Therefore, AmeriLithium Corp., headquartered in Henderson, NV and trading at $0.0086 per share with a market cap of $1.48 million, stands to skyrocket as they continue to set up drilling operations for more than one of the world’s hottest subterranean treasures. In other words, not only is the company sitting on some of the most coveted lithium properties in the U.S., which has exponential potential if countries like China impose restrictions on exports like they do with rare earth metals, but now, AMEL is looking to start mining for gold in the ripe Katanning region of Western Australia .

Amerilithium has acquired more than 700,000 acres of exploration land including three in Australia, one in Alberta, Canada and four projects based in Nevada – near the only lithium producing plant on American soil. These holdings form one of the largest portfolios in North America, and the future is bright for AMEL. In July 2012, the company finished a geophysical study of their Australian holdings and targeted their drilling sites. In late August, the company announced the receipt of permits from the U.S. Bureau of Land Management to drill up to ten holes per property on both its Jackson Wash and Clayton Deep lithium projects in Nevada. Let the drilling begin.

In the short term, as gold prices peak, perhaps the search in Katanning is more immediately enticing than the seemingly long-term payoff of lithium mining. AMEL is joining the Australian gold rush at a very profitable juncture. Companies like Newmont Boddington Gold (NYSE: NEM) and Ausgold Limited (ASX: AUC.AX) have proven reserves of 20 million and 5 million ounces in Katanning respectively.

Better still, AMEL is currently in the final stages of securing the services of a new geologist and drill team. The company is also negotiating land access deals with land owners at a low price for each hole that’s drilled. The gold potential of the Katanning project tenements were evaluated by grid soils, regional tracking and trail soil sampling, and harvesting should conclude in late January of 2013 to allowing for initiation of the drill program.

All three of AMEL’s tenements are situated within the Katanning Greenstone Belt region – a veritable hotbed of gold anomalies. Further exploration via air-core drilling by Ausgold Limited (ASX: AUC) and others, including Amerilithium’s Australian holding company (South West Minerals), will likely extend this belt’s dimensions in all directions. In other words, AMEL has already staked its claim, so what’s next? Well, drill…baby…drill. For more information on this company and the lithium/gold industry markets, visit www.amerilithium.com/

Always review our disclaimer/disclosure pertaining to this article http://tomorrowsbluechips.com/disclaimer/Tweet

While it is rare for the always-reliable and steady life sciences industry to make waves in the press, one company with a long-lasting reputation of nearly a decade has recently forged something of a comeback, receiving headlines the likes of which many younger companies would be envious.  Pressure BioSciences, Inc, (PBIO) currently trading at .22 cents with an average volume of 19,254, has been reporting record numbers throughout the year.  PBIO is a life sciences company which focuses on the development and sale of pressure-based technologies used for analyzing cells and molecules in the fields of forensics, bio-marker discovery, vaccine development, and even counter-bioterror applications.

As demand for these technologies has ballooned over the past several years, Pressure BioSciences has reaped the benefits.  In 2012, total sales for Quarter Three reached a 40% increase over the prior year period, and sales of their proprietary PCT (“Pressure Cycling Technology”) products and services climbed to a 37% increase.  Grant revenue also increased significantly over that same period, while operating losses decreased.

If that isn’t a financially sound business model, we don’t know what is.  And when it comes to financial investments, as anyone skeptical of Pressure BioSciences’ current surge of growth can not only look at the numbers, but also a handful of the Company’s recent accomplishments, to decide whether PBIO is a solid investment.

On November 26^th, Pressure BioSciences greatly expanded its product line by entering into a two-way marketing, selling, and distribution agreement with Constant Systems, to offer that company’s “cell disruption equipment and consumables” to consumers all over North America.  On the flip side, Constant Systems will offer PBIO’s PCT technologies in countries throughout Europe – a move that exponentially increases Pressure BioSciences’ exposure and potential revenue, beginning immediately in Q1 2013.

Keen to express his enthusiasm for the deal, Pressure BioSciences, Inc. President and CEO Richard T. Schumacher was quoted as saying: “the two product lines complement each other exceedingly well.  While both the CS and PBI technologies are based on high pressure, each product line has fundamental scientific capabilities that the other does not have.  PBI’s PCT Platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects.  CS’s technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing.”

This is great news not only for both of these companies, but also for PBIO’s diverse multitude of research-based consumers, which includes Harvard University, the FBI, and agricultural giant Monsanto, as the ability to access these complementary technologies from Pressure BioSciences, without having to negotiate with a third party or import technologies from overseas, will no doubt help make consumer operations run more economically and efficiently.

Pressure BioSciences is undoubtedly a seasoned company with a new agenda.  In addition to their other recent accomplishments, including their distribution deal with Thermos Fisher’s subsidiary Cole Parmer (announced last month), their deal with Constant Systems alone guarantees them a wealth of new opportunities over the course of the next year, beginning immediately. Investors looking for an undervalued stock with the potential for serious short-term gains and long-term stability need look no further than PBIO.

Always read our full disclaimer/disclosure pertaining to this article

http://tomorrowsbluechips.com/disclaimer/Tweet

For better and/or worse, technology, in almost all sectors, continues to excel at a faster rate than ever before…exponentially even. Thus, the last decade has seen a multitude of new markets arise – particularly with technologies that function synergistically with our increasingly “green” society. One of the most prominent of these fast-growing markets is that of lithium battery energy storage. The global lithium battery market is expected to grow at a steady rate of almost 14 percent every year through 2015 as the cost of manufacturing plummets, and everything from laptop computers to tablets and our hybrid and electric vehicles employ them. As the demand for stable electric grids becomes a major focus for most economies, lithium battery energy storage will also become a key component in efficiently solving the energy storage equation.

Naturally, the ones with knowledge and expertise in the electric vehicle market have a head start. Companies such as Exide Technologies (NASDAQ: XIDE), Ultralife Corp (NASDAQ: ULBI) and Balqon Corporation (OTCBB: BLQN) are all racing to corner this emerging energy market. But, Balqon may have the edge as the dark horse here. Not only has this small cap out of Los Angeles County, CA become a leading developer and manufacturer of proprietary electric drive systems for zero-emissions tractors, trucks and buses since its inception in 2005, but the company has also firmly embraced the essential shift into lithium-ion battery storage. In other words, BLQN has made its name by cleanly hauling heavy freight at marine terminals, warehouses and inner cities, but now it’s hunkering down for what some call “The Green Revolution.”

Balqon Corporation, now headquartered in Harbor City, CA, currently trades at $0.22 per share with a market cap of $9.2 million. The company possesses a executive team and a company CEO with more than 20 years of executive experience in the field of electric vehicles and chemistry chops to boot in Balwinder Samra. In addition to striking a deal with the Port of Los Angeles to develop the world’s first zero-emission electric tractors to move 30 ton containers at marine terminals and pioneering Lithium Iron Phosphate technology, BLQN introduced charging systems that vary in capacity from 8 kilo watt to 160 kilo watt in power and 200 volts to 700 volts in charge voltage.

More recently, Balqon bestowed renewable energy upon the Bourns College of Engineering building at the University of California, Riverside Campus with its Megawatt Hour storage system on top of being awarded a grant to produce three on-road Class 8 Electric trucks for the Department of Energy.  In addition, the company’s HIQAP series – a new high capacity lithium battery with more than 20 percent more efficiency than the previous model – is miles ahead of the current and standard technology of lead acid batteries.

The biggest indicator of vast diversification, however, came a month ago when BLQN announced the release of its HIQAP-GS series. The expansion pack was intended for one purpose: to replace the lead acid battery that powers most airport baggage tractors. In late September, the HIQAP-GS™ battery packs wowed audiences while on display at the International Airport Exposition in Las Vegas. CEO Balwinder Samra had this to say:

“Ability to fast charge HIQAP-GS™ batteries in less than one hour will allow customers to use existing electric tractors for two shift operations. Features such as zero maintenance, and double the life than a lead acid battery, can be the catalyst that accelerates transition of airports towards zero emission technologies.”

This past August, the stock broke out more than 20 percent higher during early trading and moved as high as 26 percent during mid-day on higher-than-average volume of 81,973 shares. If nothing else, this is one of many bits of proof for the growing momentum of Balqon Corporation as well as the value of lithium-ion batteries in utility-scale energy storage markets. With an array of proprietary lithium batteries, including the company’s new 12, 24, and 48 volt HIQAP configurations, BLQN is making lead acid batteries a thing of the past, and clean efficiency a thing of the future. The obvious potential spans more than one renewable energy industry and therefore many markets as well. To put it bluntly, investors that bank on Balqon will help solidify two revolutions: The technological and the ecological.

Always read full disclaimer/disclosure pertaining to this article: http://tomorrowsbluechips.com/disclaimer/Tweet

“It’s time to change the conversation about concussions and Traumatic Brain Injury in the NFL,” said Toi Cook, Amarantus’ newly appointed advisor. “We have been so focused on who is to blame for the rash of devastating results of brain injuries suffered while playing, that we have lost focus on the actual players who need help. Amarantus is working on breakthrough science that could ultimately treat concussions, brain injuries and their long-term side effects. This is the type of program that needs to be highlighted to the powers that be in the NFL and the NFLPA and we, as former players, need to be pushing the NFL and NFLPA to focus on providing support for research teams that are seeking to develop new treatments such as MANF that have the potential to fundamentally treat the devastating results of the brain injuries.”

Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994 Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.

“Toi will be a great addition to our Board of Advisors,” said Gerald E. Commissiong, President & CEO of Amarantus. “He has deep-rooted connections into the NFL and the NFLPA at the highest levels, and understands the need to bring the various communities involved in Traumatic Brain Injury together in order to effect meaningful change in the conversation related to TBIs from a discourse about blame, to a discourse about finding solutions through medical science.  We will work together to bring the #C4CT program to the forefront of this discussion. There are treatments in development that need further support to ensure these programs have the necessary resources to move forward. We need leadership from groups like the NFL and NFLPA if we are to effect meaningful change in the area of TBI by bringing developers and patients together.”

In recent years, the link between multiple concussions and long-term disability or brain disease has received significant scientific support. Recent studies have made clear scientific links between football-style hits and long-term brain diseases such as Parkinson’s disease, Alzheimer’s disease and Chronic Traumatic Encephalopathy. Increasing evidence supports the notion that mis-folded proteins play a critical role in the long-term side effects of concussions. Amarantus believes that MANF, which is selectively upregulated by glial cells in response to ischemia-induced neural injury and protects brain cells from chemically induced brain injury, will play a role in protecting brain cells from injury within the context of Traumatic Brain Injury.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus’ PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus’ new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus’ new product candidates, including those identified under “Risk Factors” in Amarantus’ most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

Amarantus Bioscience, Inc.
(408) 737-2734Tweet

Howard Gostfrand, President of American Capital Ventures, commented, “We believe that Magnolia Solar is positioned as a competitive provider of high efficiency thin film solar cell technology, with the opportunity to penetrate a variety of high growth public and private sectors. As the recipient of several grants, we see great potential in their patent applications and their growth prospects ahead. We look forward to working alongside management to communicate their growth story to the investment community and boost their overall investor relations efforts in key renewable energy, nanotechnology and growth markets.”

“We are pleased to have ACV on board assisting us in our investor relations initiatives,” stated Dr. Ashok K. Sood, President and CEO of Magnolia Solar Corporation. “Together, we are focused on better communicating the potential of our high efficiency thin film solar cell technologies to investors with a view to achieving a fairer valuation in the market and increasing shareholder value now and sustaining it for the future.”

About Magnolia Solar Corporation

Based in Woburn, MA and Albany, NY, Magnolia Solar was founded in 2008 to develop and commercialize revolutionary new thin-film solar cell technologies that employ nanostructured materials and designs. Both higher current and voltage outputs are expected from thin-film solar cells that combine Magnolia’s exclusive material structures with advanced optical coatings. Magnolia’s patent-pending technology has the ability to capture a larger part of the solar spectrum to produce high efficiency solar cells, and incorporates a unique nanostructure-based antireflection coating technology to further increase the solar cell’s efficiency, thereby reducing the cost per watt. Magnolia Solar technology targets electrical power generation applications, such as power for electrical grids and distributed power applications ranging from commercial and residential lighting to specialized military applications.

For more information, please visit www.MagnoliaSolar.com, or visit us on Facebook, Twitter, You Tube, or LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.Tweet

ALBANY, NY–(Marketwire – Nov 28, 2012) – Magnolia Solar Corporation ( OTCBB : MGLT ) (“Magnolia Solar”), developer of revolutionary thin-film solar cell technologies employing nanostructured materials and designs, announced that Dr. Roger E. Welser, the Chief Technology Officer of its wholly owned subsidiary, Magnolia Solar, Inc., presented a paper at the 2012 MRS Fall Meeting in Boston, MA titled “Nanostructured Transparent Conductive Oxides for Photovoltaic Applications,” as part of a special session on Photovoltaic Technologies. In addition, Dr. Welser will also be a Session Chair for the Session titled “New Concepts, Materials and Technologies for Future Photovoltaics” to be held on Wednesday, November 28, 2012.

Dr. Welser’s presentation discussed the use of advanced optical coatings of nanostructured transparent conductive oxide materials that can enhance photovoltaic device performance by minimizing reflection losses and increasing the optical path length within thin-film solar cells. He also discussed the use of nanostructured indium tin oxide (ITO) materials in antireflection structures with a step-graded refractive index design. Such conductive, high-performance optical structures on the front and back surfaces of a thin-film solar cell can potentially increase both the current and voltage output by scattering unabsorbed and emitted photons back into the active region of the device.

Photovoltaic devices can provide a mobile source of electrical power for a variety of defense and commercial applications in both space and terrestrial environments. Many of these mobile power applications can directly benefit from enhancements in the efficiency of the photovoltaic devices. Dr. Ashok K. Sood, President and CEO of Magnolia Solar Corporation, stated, “Dr. Welser’s presentation is a part of the steps we are working on to improve the performance of flexible, thin-film solar cells by employing novel, nanostructured materials, filing patents to protect our intellectual property, and continuing to make progress in further improving our optical coating technologies. These coatings, in combination with other innovative device designs, have the potential to enable flexible photovoltaic devices to reach new levels of performance for power output efficiency and it is important that we share these findings with the industry.”

The Materials Research Society (MRS) is an organization of materials researchers from academia, industry, and government that promotes communication for the advancement of interdisciplinary materials research to improve the quality of life. Founded in 1973, MRS consists of over 16,000 members from the United States — as well as nearly 70 other countries.

About Magnolia Solar Corporation

Based in Woburn, MA and Albany, NY, Magnolia Solar was founded in 2008 to develop and commercialize revolutionary new thin-film solar cell technologies that employ nanostructured materials and designs. Both higher current and higher voltage outputs are expected from thin-film solar cells that combine Magnolia’s exclusive material structures with advanced optical coatings. Magnolia’s patent-pending technology has the ability to capture a larger part of the solar spectrum to produce high efficiency solar cells, and incorporates a unique nanostructure-based antireflection coating technology to further increase solar cell efficiency, thereby reducing the cost per watt. The company is targeting a variety of civilian and defense applications for its photovoltaic solar cells. Magnolia’s solar cell technology can be used to generate power for existing electrical grids, and is particularly well-suited for distributed and portable power generation applications.

For more information, please visit www.MagnoliaSolar.com, or visit us on Facebook, Twitter, You Tube, or LinkedIn.

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.Tweet